LILRB1 and neoplasm: Additionally, DC express the SIRPα receptor and the leukocyte immunoglobulin-like receptor B1 (LILRB1), which, respectively, recognize CD47 and MHC class I-associated β2M subunits at the surface of tumor cells, blocking phagocytosis [105,106].